In 2009, the UK myeloma forum (UKMF) and the Nordic Myeloma Study Group (NMSG) produced guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
M-proteins are frequently detected in patients who are under the care of a general practitioner or a non-haematologist. The objective was to provide guidance to healthcare professionals who are often uncertain how to appropriately manage these patients in primary care.
The guidelines summarised below refer only to those patients defined as monoclonal gammopathy of undetermined significance (MGUS) with a newly detected M-protein.
